drugset / Trial / NCT00697697
A Study of 2 Doses of MAP0010 in Asthmatic Children
Phase 3
Terminated
192 enrolled
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-08
- Completion
- 2009-12
Outcome
Outcome not reported
Stopped: “Corporate decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.135 mg | Other |
| Subject | Budesonide | Small molecule | 0.25 mg | Other |